1162002

USP

Cytarabina

Name: Cytarabina
Brand: USP
Price: 1910 PLN

United States Pharmacopeia (USP) Reference Standard

Synonim(y):

Cytosine β-D-arabinofuranoside, (β-D-Arabinofuranosyl)cytosine, Ara-C, Arabinocytidine, Arabinosylcytosine, Cytarabine, Cytosine arabinoside

Slide 1 of 1

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

250 MG

1910,00 zł

Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):

C₉H₁₃N₃O₅

Numer CAS:

147-94-4

Masa cząsteczkowa:

243.22

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329749501

MDL number:

MFCD00066487

Beilstein/REAXYS Number:

89175

Kluczowe dokumenty

Wyświetl całą dokumentację

Przejdź do

Pomoc techniczna

Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.

Pozwól nam pomóc

Nazwa produktu

Cytarabina, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI key

UHDGCWIWMRVCDJ-CCXZUQQUSA-N

grade

pharmaceutical primary standard

API family

cytarabine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... POLA1(5422), POLA2(23649), POLD1(5424), POLD2(5425), POLD3(10714), POLD4(57804), POLE(5426), POLE2(5427), POLE3(54107), PRIM1(5557), PRIM2(5558)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

Reference Materials

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja	BP383	C3350000	PHR1787
USP 1162002 Cytarabina	BP383 Cytarabine	C3350000 Cytarabine	Supelco PHR1787 Cytarabine
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard
manufacturer/tradename USP	manufacturer/tradename BP	manufacturer/tradename EDQM	manufacturer/tradename -
format neat	format neat	format neat	format neat
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical pharmaceutical small molecule	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)
API family cytarabine	API family cytarabine	API family cytarabine	API family cytarabine
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C

Application

Wzorzec referencyjny cytarabiny USP, przeznaczony do stosowania w określonych testach jakości i oznaczeniach, jak określono w kompendiach USP. Również do użytku z monografiami USP, takimi jak:

Cytarabina do wstrzykiwań

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Biochem/physiol Actions

Ara-C incorporates into DNA and inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation; does not inhibit RNA synthesis. Anti-leukemia agent.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Related product

Numer produktu

Opis

Cennik

C3350000

Cytarabine, European Pharmacopoeia (EP) Reference Standard

BP383

Cytarabine, British Pharmacopoeia (BP) Reference Standard

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H317,H361fd

pcodes

P202 - P261 - P272 - P280 - P302 + P352 - P308 + P313

Hazard Classifications

Repr. 2 - Skin Sens. 1

Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Synapses on sympathetic neurons and parasympathetic neurons differ in their vulnerability to diabetes.

Alona Rudchenko et al.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(26), 8865-8874 (2014-06-27)

Synapses in autonomic ganglia represent the final output of various CNS structures that regulate the function of the periphery. Normally, these excitatory cholinergic-nicotinic synapses produce large suprathreshold EPSPs on sympathetic and parasympathetic neurons to convey signals from the CNS. However

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.

M R Sapienza et al.

Leukemia, 28(8), 1606-1616 (2014-02-08)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.

Erinn S Gideons et al.

Proceedings of the National Academy of Sciences of the United States of America, 111(23), 8649-8654 (2014-06-10)

Ketamine is an NMDA receptor (NMDAR) antagonist that elicits rapid antidepressant responses in patients with treatment-resistant depression. However, ketamine can also produce psychotomimetic effects that limit its utility as an antidepressant, raising the question of whether the clinically tolerated NMDAR

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

H Yang et al.

Leukemia, 28(6), 1280-1288 (2013-11-26)

Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from

Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?

Fazila Asmar et al.

Oncotarget, 5(7), 1912-1925 (2014-04-12)

MiR34A, B and C have been implicated in lymphomagenesis, but information on their role in normal CD19+ B-cells (PBL-B) and de novo diffuse large B-cell lymphoma (DLBCL) is limited. We show that in normal and activated B-cells miR34A-5p plays a

Wyświetl wszystkie powiązane dokumenty

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej